July 27, 2017 3:14 AM ET

Biotechnology

Company Overview of Akebia Therapeutics, Inc.

Company Overview

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product candidates that include AKB-6899 for the treatment of anemia; and AKB-5169, a preclinical compound for the treatment for inflammatory bowel disease. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. ...

245 First Street

Suite 1100

Cambridge, MA 02142

United States

Founded in 2007

89 Employees

Phone:

617-871-2098

Fax:

617-871-2099

Key Executives for Akebia Therapeutics, Inc.

Chief Executive Officer, President and Director
Age: 53
Total Annual Compensation: $775.7K
Chief Financial Officer, Senior Vice President and Treasurer
Age: 49
Total Annual Compensation: $476.0K
Medical Advisor
Age: 64
Total Annual Compensation: $572.8K
Compensation as of Fiscal Year 2016.

Akebia Therapeutics, Inc. Key Developments

Akebia Therapeutics, Inc. - Analyst/Investor Day

Akebia Therapeutics, Inc. - Analyst/Investor Day

Akebia Therapeutics, Inc. Presents at JMP Securities Life Sciences Conference 2017, Jun-21-2017 01:00 PM

Akebia Therapeutics, Inc. Presents at JMP Securities Life Sciences Conference 2017, Jun-21-2017 01:00 PM. Venue: St. Regis Hotel, 2 East 55 Street, New York, New York, United States.

Akebia Therapeutics Appoints Rita Jain as Chief Medical Officer

Akebia Therapeutics, Inc. announced the appointment of Rita Jain, M.D. as Senior Vice President and Chief Medical Officer. Dr. Jain will be responsible for leading the clinical development of the Company’s HIF pipeline, including the global Phase 3 development program for vadadustat, an oral HIF stabilizer in development for the treatment of anemia related to chronic kidney disease. Dr. Jain succeeds Brad Maroni, M.D. who will remain at Akebia as a medical advisor. Dr. Jain joins Akebia from AbbVie where she most recently was the Vice President of Men’s and Women’s Health and Metabolic Development.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
May 12, 2017
--
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Akebia Therapeutics, Inc., please visit www.akebia.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.